Initial score on the Pemphigus Disease Area Index and evolution of anti-desmoglein antibody values 3 months after an initial cycle of rituximab are associated with short-term pemphigus relapse, according to a post hoc analysis of a randomized clinical trial published in JAMA Dermatology.
